Please login to the form below

Not currently logged in
Email:
Password:

UK pledges £220m tech fund for life science and university sectors

ABPI says investment will be well received by the pharma industry
ABPI

The UK government is set to invest £220m in a package of measures for the life science and university sectors to support the use of cutting edge technologies.

The support was announced by the chancellor Philip Hammond over the weekend and half of it will be tailored to help translate medical technology breakthroughs into commercial success.

The investment was welcomed by industry body the ABPI, which said it "demonstrates the Government's continued support for the UK life sciences industry".

Chief executive Mike Thompson hailed the four-year funding plan as a “clear signal from Government that the UK remains a great place for life sciences and will be well received by all in the industry”.

Nearly half of the funding - £100m - has been earmarked for the Biomedical Catalyst (BMC), an accelerative novel products programme created by the government-funded bodies Medical Research Council and Innovate UK.

This will see grants awarded for the development of disruptive healthcare technologies in disease prevention, earlier diagnosis and personalised medicines from feasibility studies through to early clinical trials.

The remaining £120m will be used to incentivise academic collaborations with pharma and other sectors, sharing technologies to help transform university-led research into viable business ventures, like Nottingham University's cancer detection project Oncimmune which is developing a blood test for lung cancer.

Commenting on the announcement, which came on the eve of the Conservative Party conference in Birmingham, Thompson said: “We hope that today's investment is just a first step.

“We look forward to the publication of the Accelorated Access Review in the coming weeks which should drive further investment and innovation in our sector and help improve access to innovative medicines and treatments for NHS patients.”

Article by
Rebecca Clifford

3rd October 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics